Loading...
Loading...
Browse all stories on DeepNewz
VisitHow many emergency room visits due to mRNA COVID-19 vaccines will be reported by the end of 2024?
Less than 80,000 • 25%
80,000 to 90,000 • 25%
90,000 to 100,000 • 25%
More than 100,000 • 25%
VAERS (Vaccine Adverse Event Reporting System) database
FDA Affirms Safety of mRNA COVID-19 Vaccines Amid Cancer Claims and 600,000 Adverse Events
Sep 6, 2024, 08:42 PM
Recent discussions around the mRNA COVID-19 vaccines have highlighted both their efficacy and safety, as well as concerns about potential adverse effects. Findings from the COVE trial indicate that the mRNA-1273 vaccine is safe and effective against COVID-19, including emergent variants. Dr. Peter Marks from the FDA has affirmed the agency's confidence in the safety and effectiveness of these updated vaccines, noting that they meet rigorous scientific standards. AmeshAA stated, “With the mRNA technology, we're able to produce a vaccine that gives quite potent responses with a very tolerable safety profile.” However, there are claims circulating that Moderna's mRNA vaccines cause cancer and other adverse events. Over 600,000 adverse events have been reported in the United States, including 75,000 ER visits and 36,000 hospitalizations. These claims are juxtaposed with the FDA's assurance of the vaccine's safety profile.
View original story
0-10 • 25%
11-50 • 25%
51-100 • 25%
101 or more • 25%
Less than 200 • 25%
200 to 300 • 25%
301 to 400 • 25%
More than 400 • 25%
0-100 • 25%
101-500 • 25%
501-1000 • 25%
More than 1000 • 25%
Less than 10,000 • 25%
10,000 to 50,000 • 25%
50,001 to 100,000 • 25%
More than 100,000 • 25%
No issues found • 25%
Minor issues found • 25%
Significant issues found • 25%
Undetermined • 25%
None reported • 25%
Few minor events • 25%
Significant events • 25%
Major public health concern • 25%
Less than 90% • 25%
90% to 95% • 25%
96% to 99% • 25%
100% • 25%
Less than 1 million • 25%
1-5 million • 25%
5-10 million • 25%
More than 10 million • 25%
None • 25%
Mild • 25%
Moderate • 25%
Severe • 25%
22-30 • 25%
31-40 • 25%
41-50 • 25%
More than 50 • 25%
Less than 50 • 25%
50 to 100 • 25%
100 to 200 • 25%
More than 200 • 25%
No • 50%
Yes • 50%
Yes • 50%
No • 50%
More than 60,000 • 25%
50,000 to 60,000 • 25%
Less than 40,000 • 25%
40,000 to 50,000 • 25%